Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the safety, tolerability, and pharmacokinetics/pharmacodynamics of crinecerfont in children under 4 with classic congenital …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• Crinecerfont (crinecerfont)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Congenital Adrenal Hyperplasia | Phase 2 | Status: NOT_YET_RECRUITING